Upper airway resistance syndrome (UARS)

Upper airway resistance syndrome is not a molecule, receptor, enzyme, transporter, or other canonical therapeutic target. Instead, it is a clinical sleep disorder characterized by increased resistance to airflow in the upper airway during sleep. This leads to frequent arousals and disrupted sleep but without the significant oxygen desaturation seen in obstructive sleep apnea[3][5][6]. Symptoms include excessive daytime drowsiness, insomnia, chronic fatigue, unrefreshing sleep, headaches, and sometimes hypotension[1][3][6]. The underlying cause is typically anatomical narrowing of the upper airway due to soft tissue relaxation or tongue position during sleep[1][8]. Diagnosis relies on polysomnography with esophageal manometry or airflow measurements rather than identification of a specific biomolecule or receptor[2][5]. Treatments focus on mechanical solutions such as continuous positive airway pressure (CPAP), oral appliances that reposition the jaw/tongue, lifestyle changes (weight loss if indicated), and occasionally surgery—none of which target a specific molecule but rather address physical obstruction[1][8]. Because "upper airway resistance" refers to a physiological phenomenon/disorder and not an individual protein/gene/receptor/enzyme/transporter/etc., it should not be considered a therapeutic target in the conventional sense, nor does it have canonical aliases/molecular classifications/abbreviations beyond its clinical acronym UARS. If you are seeking information about an actual molecular target involved in upper airway tone regulation—such as muscarinic acetylcholine receptors controlling pharyngeal muscle tone—that would require specifying those molecules directly.

Other names

UARSsleep-disordered breathing variant

Not applicable (treatments act mechanically, not via molecular interaction)